284 related articles for article (PubMed ID: 20529296)
1. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.
Adamski J; Godman B; Ofierska-Sujkowska G; Osińska B; Herholz H; Wendykowska K; Laius O; Jan S; Sermet C; Zara C; Kalaba M; Gustafsson R; Garuolienè K; Haycox A; Garattini S; Gustafsson LL
BMC Health Serv Res; 2010 Jun; 10():153. PubMed ID: 20529296
[TBL] [Abstract][Full Text] [Related]
2. [Risk sharing methods in middle income countries].
Inotai A; Kaló Z
Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
[TBL] [Abstract][Full Text] [Related]
3. [Risk-sharing schemes: a new paradigm in adopting innovative pharmaceuticals].
Hammerman A; Greenberg D
Harefuah; 2012 Jun; 151(6):364-7, 376. PubMed ID: 22991869
[TBL] [Abstract][Full Text] [Related]
4. Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement.
Neumann PJ; Chambers JD; Simon F; Meckley LM
Health Aff (Millwood); 2011 Dec; 30(12):2329-37. PubMed ID: 22147861
[TBL] [Abstract][Full Text] [Related]
5. Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products.
Towse A; Garrison LP
Pharmacoeconomics; 2010; 28(2):93-102. PubMed ID: 20085386
[TBL] [Abstract][Full Text] [Related]
6. Examining Misaligned Incentives for Payers and Manufacturers in Value-Based Pharmaceutical Contracts.
Kannarkat JT; Good CB; Kelly E; Parekh N
J Manag Care Spec Pharm; 2020 Jan; 26(1):63-66. PubMed ID: 31880231
[TBL] [Abstract][Full Text] [Related]
7. Risk sharing or risk shifting? On the development of patient access schemes in the process of updating the national list of health services in Israel.
Triki N; Ash N; Porath A; Birnbaum Y; Greenberg D; Hammerman A
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):749-753. PubMed ID: 31825682
[No Abstract] [Full Text] [Related]
8. When are Pharmaceuticals Priced Fairly? An Alternative Risk-Sharing Model for Pharmaceutical Pricing.
Balderrama F; Schwartz LJ; Longo CJ
Health Care Anal; 2020 Jun; 28(2):121-136. PubMed ID: 32232611
[TBL] [Abstract][Full Text] [Related]
9. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.
Garrison LP; Towse A; Briggs A; de Pouvourville G; Grueger J; Mohr PE; Severens JL; Siviero P; Sleeper M
Value Health; 2013; 16(5):703-19. PubMed ID: 23947963
[TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical risk-sharing agreements.
Cook JP; Vernon JA; Manning R
Pharmacoeconomics; 2008; 26(7):551-6. PubMed ID: 18563946
[TBL] [Abstract][Full Text] [Related]
11. End of life or end of the road? Are rising cancer costs sustainable? Is it time to consider alternative incentive and funding schemes?
McGuire A; Drummond M; Martin M; Justo N
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):599-605. PubMed ID: 26176751
[TBL] [Abstract][Full Text] [Related]
12. Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experience.
Dunlop WCN; Staufer A; Levy P; Edwards GJ
Health Policy; 2018 May; 122(5):528-532. PubMed ID: 29567205
[TBL] [Abstract][Full Text] [Related]
13. Performance-Based Risk-Sharing Arrangements (PBRSA): Is it a Solution to Increase Bang for the Buck for Pharmaceutical Reimbursement Strategy for Our Nation and Around the World?
Kim AE; Choi DH; Chang J; Kim SH
Clin Drug Investig; 2020 Dec; 40(12):1107-1113. PubMed ID: 33037566
[TBL] [Abstract][Full Text] [Related]
14. The current performance-linked and risk sharing agreement scene in the Spanish region of Catalonia.
Darbà J; Ascanio M
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):743-748. PubMed ID: 30821532
[No Abstract] [Full Text] [Related]
15. Pharmaceutical Pricing and Market Access Outlook Europe 2010-HealthNetwork Communications' fourth annual conference. 24-25 March 2010, London, UK.
Ogbighele E
IDrugs; 2010 May; 13(5):317-20. PubMed ID: 20432188
[TBL] [Abstract][Full Text] [Related]
16. Private sector risk-sharing agreements in the United States: trends, barriers, and prospects.
Garrison LP; Carlson JJ; Bajaj PS; Towse A; Neumann PJ; Sullivan SD; Westrich K; Dubois RW
Am J Manag Care; 2015 Sep; 21(9):632-40. PubMed ID: 26618366
[TBL] [Abstract][Full Text] [Related]
17. Specialty pharmacies and other restricted drug distribution systems: financial and safety considerations for patients and health-system pharmacists.
Kirschenbaum BE
Am J Health Syst Pharm; 2009 Dec; 66(24 Suppl 7):S13-20. PubMed ID: 19966075
[TBL] [Abstract][Full Text] [Related]
18. The impact of two pharmaceutical risk-sharing agreements on pricing, promotion, and net health benefits.
Zaric GS; Xie B
Value Health; 2009; 12(5):838-45. PubMed ID: 19490563
[TBL] [Abstract][Full Text] [Related]
19. How to solve financing gap to ensure patient access to patented pharmaceuticals in CEE countries? - the good, the bad, and the ugly ways.
Inotai A; Kaló Z
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):627-632. PubMed ID: 31810392
[No Abstract] [Full Text] [Related]
20. Importance of aligning the implementation of new payment models for innovative pharmaceuticals in European countries.
Kaló Z; Niewada M; Bereczky T; Goettsch W; Vreman RA; Xoxi E; Trusheim M; Callenbach MHE; Nagy L; Simoens S
Expert Rev Pharmacoecon Outcomes Res; 2024 Feb; 24(2):181-187. PubMed ID: 37970637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
